| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22064 |
| Drug | Teclistamab |
| Brand | Tecvayli® |
| Indication | As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
| Assessment Process | |
| Rapid review commissioned | 20/09/2022 |
| Rapid review completed | 03/11/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of teclistamab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/11/2022 |
| Pre-submission consultation with Applicant | 24/01/2023 |
| Full submission received from Applicant | 18/05/2023 |
| Preliminary review sent to Applicant | 06/02/2024 |
| NCPE assessment re-commenced | 07/03/2024 |
| Follow-up to preliminary review sent to Applicant | 16/04/2024 |
| NCPE assessment re-commenced | 01/05/2024 |
| Additional follow-up to Preliminary Review sent to Applicant | 09/05/2024 |
| NCPE assessment re-commenced | 10/05/2024 |
| Factual accuracy sent to Applicant | 05/06/2024 |
| NCPE assessment re-commenced | 12/06/2024 |
| NCPE assessment completed | 04/07/2024 |
| NCPE assessment outcome | The NCPE recommends that teclistamab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
